- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Viveve Reports Preliminary Second Quarter 2018 Revenue of $5.5 million
Viveve Medical (NASDAQ:VIVE), a medical technology company focused on women’s intimate health, today reported preliminary financial results for the second quarter ended June 30, 2018. Estimated total product revenue for the three months ended June 30, 2018, is expected to be approximately $5.5 million, representing a 79% increase over total product revenue for the quarter …
Viveve Medical (NASDAQ:VIVE), a medical technology company focused on women’s intimate health, today reported preliminary financial results for the second quarter ended June 30, 2018. Estimated total product revenue for the three months ended June 30, 2018, is expected to be approximately $5.5 million, representing a 79% increase over total product revenue for the quarter ended June 30, 2017. The company also announced today that it has entered into a capital sales partnership with Aesthetic Management Partners, Inc. (“AMP”) to expand its commercial footprint in the U.S.
As quoted in the press release:
“This quarter’s preliminary total revenue reflects the impact of several recent positive developments, including the restructuring and expansion of our sales organization in the first quarter of 2018, positive clinical data from our clinical research in stress urinary incontinence in February and June, and growing adoption of our CMRF platform and single treatment procedures by physicians around the world. We are also planning for expansion of our U.S. footprint with the addition of the experienced capital sales team at AMP. With these developments in place, we believe we are well-positioned for further growth in adoption and utilization of our technology and remain on track to meet our full year revenue guidance of $22-$24 million,” said Scott Durbin, chief executive officer and director of Viveve.
Under its partnership with AMP, Viveve will retain its direct sales organization consisting of four regional sales directors, 23 capital representatives, and 10 practice development managers while expanding coverage with the addition of approximately 20 AMP capital representatives. The partnership with AMP also provides a cross-organizational bundled sales opportunity with Viveve technology positioned as the core product offering. Viveve’s newly launched practice development management team will continue to support all current and future utilization and growth for the U.S. installed customer base.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.